News
EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) to enter clinical development. It selectively targets a tumour-specific N-glycosylated epitope on both CEACAM5 and CEACAM6.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback